1086383-70-1

Basic information

• Product Name: Pyridazine, 3-broMo-6isopropyl
• Synonyms: Pyridazine, 3-broMo-6isopropyl;3-BroMo-6-isopropylpyridazine
• CAS NO: 1086383-70-1
• Molecular Formula: C7H9BrN2
• Molecular Weight: 201.06376
• Mol File: 1086383-70-1.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 297.9±20.0 °C(Predicted)
• Appearance: /
• Density: 1.414±0.06 g/cm3(Predicted)
• PKA: 1.14±0.10(Predicted)
• CAS DataBase Reference: Pyridazine, 3-broMo-6isopropyl(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridazine, 3-broMo-6isopropyl(1086383-70-1)
• EPA Substance Registry System: Pyridazine, 3-broMo-6isopropyl(1086383-70-1)

Safety Data

• Hazardous Substances Data: 1086383-70-1(Hazardous Substances Data)

Usage

General Description

Pyridazine, 3-bromo-6-isopropyl is a chemical compound with the molecular formula C8H9BrN2. It is a brominated derivative of pyridazine and contains an isopropyl group. Pyridazine, 3-broMo-6isopropyl is commonly used in organic synthesis as a building block for various pharmaceuticals and agrochemicals. Its unique structure and reactivity make it a valuable intermediate in the production of biologically active compounds. Additionally, it has potential applications in the development of new materials and research in the field of organic chemistry. However, it is important to handle this compound with care as it may be hazardous if not handled properly.

Upstream product

• 570416-36-3 6-isopropylpyridazin-3(2H)-one 
• 563-80-4 3-methyl-butan-2-one 

Relevant articles and documents

Synthesis of a CGRP Receptor Antagonist via an Asymmetric Synthesis of 3-Fluoro-4-aminopiperidine

A practical and efficient enantioselective synthesis of the calcitonin gene-related peptide receptor antagonist 1 has been developed. The key structural component of the active pharmaceutical ingredient is a syn-1,2-amino-fluoropiperidine 4. Two approaches were developed to synthesize this important pharmacophore. Initially, Ru-catalyzed asymmetric hydrogenation of fluoride-substituted enamide 8 enabled the synthesis of sufficient quantities of compound 1 to support early preclinical studies. Subsequently, a novel, cost-effective route to this intermediate was developed utilizing a dynamic kinetic asymmetric transamination of ketone 9. This synthesis also features a robust Ullmann coupling to install a bis-aryl ether using a soluble Cu(I) catalyst. Finally, an enzymatic desymmetrization of meso-diester 7 was exploited for the construction of the γ-lactam moiety in 1.